{"id":"W2587420003","doi":"10.1093/annonc/mdw611","title":"Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":522,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency; Ottawa Hospital; McGill University","funders":"Chugai Pharmaceutical; Genentech; Ono Pharmaceutical; Astellas Pharma; Chinese University of Hong Kong; GlaxoSmithKline; AstraZeneca Korea; Clovis Oncology; Vertex Pharmaceuticals; International Association for the Study of Lung Cancer; Amgen; ACEA Biosciences; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Gefitinib; Afatinib; Medicine; Internal medicine; Lung cancer; Hazard ratio; Oncology; Epidermal growth factor receptor; T790M; Proportional hazards model; Gastroenterology; Confidence interval; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001942383,0.001186464,0.002936839,0.0002988515,0.0003782531,0.00136666,0.0006495397,0.001220256,0.002316322],"category_scores_gemma":[0.00196096,0.0003112297,0.003425864,0.000466929,0.0008407968,0.001739359,0.0003765004,0.003161561,0.0005156103],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001126021,"about_ca_system_score_gemma":0.0008270071,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001162888,"about_ca_topic_score_gemma":0.004860464,"domain_scores_codex":[0.9991938,0.0004050804,0.00006633416,0.0001181352,0.00006369178,0.0001529089],"domain_scores_gemma":[0.9991411,0.0002600115,0.0002391707,0.00006149637,0.00005738776,0.0002407749],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8252606,0.00219553,0.01354863,0.00236594,0.008695457,0.0002200778,0.0002048985,0.004875617,0.005319493,0.0005847111,0.008985129,0.1277438],"study_design_scores_gemma":[0.7642097,0.1311206,0.07346746,0.0003783233,0.009674823,0.00107826,0.0004514144,0.004586832,0.002051845,0.002847899,0.009973552,0.0001593254],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9710215,0.02166194,0.0002980435,0.001797851,0.000384098,0.0002045179,0.001263723,0.00008102508,0.003287328],"genre_scores_gemma":[0.991056,0.004427063,0.0002803992,0.0008491898,0.0002223617,0.0001495104,0.001755508,0.00002076486,0.001239192],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002936839,"threshold_uncertainty_score":0.01027244,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08223081129384406,"score_gpt":0.4570319687057121,"score_spread":0.374801157411868,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}